Dine Mark S, Hutchins Sonja S, Thomas Ann, Williams Irene, Bellini William J, Redd Stephen C
J Infect Dis. 2004 May 1;189 Suppl 1:S123-30. doi: 10.1086/380308.
Because measles-specific antibody titer after vaccination is lower than after natural infection, there is concern that vaccinated persons may gradually lose protection from measles. To examine the persistence of vaccine-induced antibody, participants of a vaccine study in 1971, with documentation of antibody 1-7 years after vaccination, were followed up in 1997-1999 to determine the presence and titer of measles antibody. Of the 56 participants (77% were 2-dose recipients), all had antibodies detected by the plaque reduction neutralization (PRN) antibody assay an average of 26-33 years after the first or second dose of measles vaccine; 92% had a PRN titer considered protective (>1 : 120). Baseline hemagglutination inhibition antibody titer in 1971 strongly predicted follow-up PRN antibody titer (P<.001). Persistence of antibody in these primarily 2-dose recipients supports the current elimination strategy to achieve and sustain high population immunity with a 2-dose schedule.
由于接种疫苗后麻疹特异性抗体滴度低于自然感染后,人们担心接种疫苗的人可能会逐渐失去对麻疹的免疫力。为了研究疫苗诱导抗体的持久性,对1971年一项疫苗研究的参与者进行了随访,这些参与者在接种疫苗1至7年后有抗体记录,于1997 - 1999年确定其麻疹抗体的存在和滴度。在56名参与者中(77%为接受两剂疫苗者),所有人在第一剂或第二剂麻疹疫苗接种后平均26 - 33年通过蚀斑减少中和(PRN)抗体检测法检测到抗体;92%的人PRN滴度被认为具有保护性(>1:120)。1971年的基线血凝抑制抗体滴度强烈预测了随访时的PRN抗体滴度(P<0.001)。这些主要接受两剂疫苗者体内抗体的持久性支持了目前通过两剂接种程序实现并维持高人群免疫力的消除策略。